- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- YM155, Rituximab
- Drug · Biological
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 6
- States / cities
- Columbus, Georgia • Maywood, Illinois • New York, New York + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- interleukin-2, rituximab
- Drug
- Lead sponsor
- Chiron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
- Conditions
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- Interventions
- Odronextamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 13
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Louisville, Kentucky + 9 more
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- Odronextamab multiple dose levels
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 10
- States / cities
- Orange, California • Stanford, California • Tampa, Florida + 4 more
- Conditions
- Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis, Radionuclide Imaging, Rituximab, Single Photon Emission Computed Tomography, Yttrium Y-90 Ibritumomab Tiuxetan
- Drug · Radiation · Other + 2 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Rochester, Minnesota
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 80
- States / cities
- Anniston, Alabama • La Jolla, California • Los Angeles, California + 60 more
- Conditions
- Previously Treated CD20+ B-cell Malignancies
- Interventions
- ocaratuzumab
- Biological
- Lead sponsor
- Mentrik Biotech, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Lymphoma, Small Lymphocytic, Lymphocytic Leukemia, Chronic
- Interventions
- Fludarabine, Rituximab, Alemtuzumab
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma
- Interventions
- PSB202
- Drug
- Lead sponsor
- Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • New York, New York
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Rituximab, Fludarabine Phosphate, Cyclophosphamide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Fresno, California + 3 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- CAMPATH (alemtuzumab)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 10
- States / cities
- Colorado Springs, Colorado • Ocala, Florida • Park Ridge, Illinois + 7 more
- Conditions
- Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
- Interventions
- Lenalidomide, Dexamethasone, Rituximab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania